medroxyprogesterone / Generic mfg. - LARVOL DELTA

Intrauterine Stent Placement Following Hysteroscopic Septum Resection (clinicaltrials.gov) - P=N/A | N=320 | Not yet recruiting | Sponsor: Weill Medical College of Cornell University | Initiation date: Oct 2025 ➔ Jan 2026 | Trial primary completion date: Jan 2028 ➔ Sep 2029

Trial initiation date • Trial primary completion date

SUNFLOWER: Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months (clinicaltrials.gov) - P3 | N=207 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting | Trial completion date: Jan 2027 ➔ May 2027 | Trial primary completion date: Jan 2027 ➔ May 2027

Enrollment open • Trial completion date • Trial primary completion date

Medroxyprogesterone Acetate Inhibits Tumorigenesis in Mouse Models of Oviductal High-Grade Serous Carcinoma. (PubMed, Cancers (Basel)) - "These findings demonstrate that a synthetic progestin, specifically MPA, confers robust protection against HGSC development, while a combination including E2 (E2 + P4) increases risk. This work also illustrates how HGSC GEMMs can be used to compare the chemo-preventive effects of various synthetic progestins on HGSC development in order to prioritize the most effective ones for use in preventing HGSC in both general and high-risk populations."

Journal • Preclinical • Colon Cancer • Colorectal Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA1 • NF1 • RB1 • TP53

SUNFLOWER: Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months (clinicaltrials.gov) - P3 | N=207 | Not yet recruiting | Sponsor: Bayer | N=300 ➔ 207

Enrollment change

Hormonal Therapy and Hepatic Risk: A Case Report of Progestin-Induced Cholestatic Liver Injury (ACG 2025) - "Here we present a case of a postmenopausal woman with end-stage liver disease and abnormal uterine bleeding requiring progestin therapy, who subsequently sustained an unusual pattern of liver injury.Case Description/ The patient is a 64-year-old female with known HIV on Biktarvy, CKD, MASH cirrhosis decompensated by ascites, non-bleeding esophageal varices, and hepatic encephalopathy with prior listing for dual kidney/liver transplant, who was admitted for postmenopausal bleeding in the setting of new cervical/uterine mass...She was started on Provera with good effect in controlling her bleeding, however her liver enzymes, bilirubin in particular, acutely worsened; AST/ALT 91/31, ALP 143 total bilirubin 19...Clinicians should maintain a high level of suspicion when evaluating patients on hormonal therapy with acutely worsening liver enzymes, regardless of the pattern of injury. It is critical to consider various differentials, in order to optimize treatment in medically..."

Case report • Clinical • Chronic Kidney Disease • CNS Disorders • Fibrosis • Gastroenterology • Hepatic Encephalopathy • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Liver Failure • Long-acting Reversible Contraceptives • Metabolic Dysfunction-Associated Steatohepatitis • Women's Health

The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Front Endocrinol (Lausanne)) - "No statistically significant changes were found in homocysteine or IL-6 levels. While MPA/CEE therapy significantly reduces CRP and fibrinogen, key inflammatory and cardiovascular risk markers, these findings suggest a notable protective effect of oral MPA/CEE on inflammation, highlighting the need for individualized therapeutic strategies based on patient risk profiles."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Inflammation • CRP • IL6

Impact of postoperative intrauterine therapies on IVF outcomes in patients with Asherman's Syndrome (ESGE 2025) - "Following catheter removal, a copper intrauterine device (IUD) was inserted, and patients received oral estradiol valerate (12–18 mg/day for 28 days) and oral medroxyprogesterone acetate (10 mg/day for the last 7 days). The complete resolution of menstrual disturbances and promising pregnancy results in both patient groups support the integration of tailored intrauterine therapies into routine clinical practice for endometrial rehabilitation prior to IVF. Further large-scale studies are warranted."

Clinical • Gynecology • Infertility • Long-acting Reversible Contraceptives • Mood Disorders • Pediatrics • Sexual Disorders • Women's Health

Endometrial regenerative therapy in patients with thin endometrium: A prospective case series (ESGE 2025) - "Postoperatively, all patients received standardized hormonal therapy with oral estradiol valerate (12–18 mg/day for 28 days) and oral medroxyprogesterone acetate (10 mg/day during the final 7 days) to induce withdrawal bleeding. The high clinical pregnancy and live birth rates observed in this cohort support the potential efficacy of this protocol. These findings underscore the need for further controlled trials to standardize treatment strategies and identify patients who may benefit most from regenerative intrauterine interventions."

Clinical • Gynecology • Infectious Disease

Effectiveness of combined clindamycin phosphate and medroxyprogesterone acetate tablets in treatment of endometritis. (PubMed, Afr J Reprod Health) - "No severe adverse reactions were observed. These findings suggest that the combination of CPT and MAT is more effective than CPT alone in alleviating symptoms, reducing inflammation, and promoting menstrual normalization in patients with endometritis."

Clinical • Journal • Endometriosis • Gynecology • Inflammation • Musculoskeletal Pain • Pain • IL4 • MMP2 • MMP9 • TGFB1 • TNFA • VCAM1

An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera (clinicaltrials.gov) - P1/2 | N=200 | Recruiting | Sponsor: Urmila DIwekar | Not yet recruiting ➔ Recruiting

Enrollment open • Infertility • Sexual Disorders

Intrauterine Stent Placement Following Hysteroscopic Septum Resection (clinicaltrials.gov) - P=N/A | N=320 | Not yet recruiting | Sponsor: Weill Medical College of Cornell University | Initiation date: Jun 2025 ➔ Oct 2025

Trial initiation date

Long-term disease-free survival after bilateral video-assisted thoracoscopic resection of multiple pulmonary metastases from endometrial stromal sarcoma: An 8-year follow-up case report. (PubMed, Gynecol Oncol Rep) - "The patient received oral medroxyprogesterone acetate for five years...She remains disease-free a total of eight years after metastasectomy. Complete resection of bilateral multiple pulmonary metastases from LG-ESS, combined with hormonal therapy, can achieve durable long-term disease control in carefully selected patients."

Journal • Video • Cardiovascular • Gynecology • Hematological Disorders • Oncology • Sarcoma • Solid Tumor • Subarachnoid Hemorrhage • Uterine Cancer • Vascular Neurology • MME • PGR

Effectiveness and Safety of Postoperative Medical Treatments Following Fertility-Preserving Surgery for Endometriosis: A Network Meta-Analysis. (PubMed, BJOG) - "LNG-IUS combined with laparoscopic surgery appears most effective in reducing recurrence and pain in EMs patients. Danazol and goserelin should be used cautiously due to notable adverse effects."

Journal • Retrospective data • Review • Endometriosis • Gynecology • Pain • Women's Health

Genomic and DNA methylomic factors associated with the efficacy of oral medroxyprogesterone acetate on endometrial neoplastic disease. (PubMed, Gynecol Oncol) - "These findings not only provide a foundation for identifying effective biomarkers for MPA efficacy, but also reveal deeper insights into the mechanism of action of progestins."

Journal • Tumor mutational burden • Endometrial Cancer • Oncology • Solid Tumor • PGR • TMB

RESToRE: Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer (clinicaltrials.gov) - P4 | N=250 | Active, not recruiting | Sponsor: University of British Columbia | Trial completion date: Oct 2024 ➔ Dec 2025 | Trial primary completion date: Oct 2024 ➔ Dec 2025 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Endometrial Cancer • Oncology • Solid Tumor • Uterine Cancer

Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting (clinicaltrials.gov) - P3 | N=126 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xinxiang Medical College

New P3 trial • Chemotherapy-Induced Nausea and Vomiting • Solid Tumor

Progestogen Experience Among Transgender Women and Gender Diverse Adults Assigned Male at Birth in the United States. (PubMed, Endocr Pract) - "In the largest survey describing progestogen experience in E-GAHT to date, over half of TGD AMAB adults used progestogens. While most report satisfaction with use, further objective evidence on the benefits of progestogens is needed to clarify its clinical impact as part of E-GAHT."

Journal • Cardiovascular • Hematological Disorders • Pain • Pulmonary Embolism • Respiratory Diseases

Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy (clinicaltrials.gov) - P2 | N=140 | Not yet recruiting | Sponsor: Peking University People's Hospital | Trial completion date: Jun 2027 ➔ Dec 2027 | Initiation date: Apr 2025 ➔ Jul 2025

Trial completion date • Trial initiation date • Endometrial Cancer • Oncology • Solid Tumor

Intrauterine Stent Placement Following Hysteroscopic Septum Resection (clinicaltrials.gov) - P=N/A | N=320 | Not yet recruiting | Sponsor: Weill Medical College of Cornell University

New trial

Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia (clinicaltrials.gov) - P2 | N=38 | Recruiting | Sponsor: Peking University People's Hospital | Trial completion date: Jun 2025 ➔ Sep 2025 | Trial primary completion date: Apr 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Endometrial Cancer • Oncology • Solid Tumor

Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy (clinicaltrials.gov) - P2 | N=140 | Not yet recruiting | Sponsor: Peking University People's Hospital

New P2 trial • Endometrial Cancer • Oncology • Solid Tumor

The effects of transdermal estrogens combined with Medroxyprogesterone Acetate on cardiovascular disease risk factors in postmenopausal women: a meta-analysis of randomized controlled trials. (PubMed, Diabetol Metab Syndr) - "Based on the results of the current meta-analysis, transdermal estrogens combined with oral MPA administration had a beneficial effect on certain CVD risk factors in postmenopausal women, as evidenced by the significant reductions in TC, LDL-C, and ApoB."

Journal • Retrospective data • Review • Cardiovascular • Dyslipidemia • APOA1 • APOB

Synchronous Endometrial and Ovarian Adenocarcinomas in a 43-Year-Old Patient Following Infertility Treatment: A Case Report. (PubMed, Diagnostics (Basel)) - "The patient also received medroxyprogesterone acetate oral treatment...Considering the young age of the patients, an early disease stage, a low grade of both cancers, and favorable prognosis, most synchronous endometrial and ovarian cancers are identified as two independent primary tumors. The diagnosis of a multi-focal neoplasm is important, as in patients with endometrial cancer and ovarian metastasis, the 5-year survival rate is 30-40%, whereas in the case of individual neoplasms, it is 75-80%."

Journal • Endometrial Cancer • Infertility • Long-acting Reversible Contraceptives • Oncology • Ovarian Cancer • Sexual Disorders • Solid Tumor • Uterine Leiomyoma

Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia (clinicaltrials.gov) - P2 | N=38 | Recruiting | Sponsor: Peking University People's Hospital | Trial primary completion date: Jan 2025 ➔ Apr 2025

Trial primary completion date • Endometrial Cancer • Oncology • Solid Tumor

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), the NCCN Drugs & Biologics Compendium (NCCN Compendium), the NCCN Radiation Therapy Compendium, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC) for Uterine Neoplasms, Version 1.2025. (NCCN)

NCCN guideline • Endometrial Cancer • Uterine Cancer • Uterine Corpus Leiomyosarcoma